NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-269-2003-0-US-04 Composition for Detecting the Response of Rectal Adenocarcinomas to Radiochemotherapy US CON 14/507,707 Abandoned
NCI E-040-2012-0-IS-14 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen IS National Stage EU9056 Pending
NCI E-771-2013-4-TW-06 Modified Pseudomonas Exotoxin A TW ORD 103134804 Abandoned
NIAID E-124-2009-0-RU-17 Influenza Hemagglutinin And Neuraminidase Variants RU DIV 2014140731 Abandoned
NCI E-771-2013-4-EP-11 Modified Pseudomonas Exotoxin A EP National Stage 14789449.7 Issued
NCI E-771-2013-4-AU-08 Modified Pseudomonas Exotoxin A AU National Stage 2014329437 Issued
NCI E-771-2013-4-US-02 Modified Pseudomonas Exotoxin A US ORD 14/505,590 9388222 Issued PDF
NCI E-771-2013-4-IN-12 Modified Pseudomonas Exotoxin A IN National Stage 201647015226 Abandoned
NCI E-771-2013-4-AR-03 Modified Pseudomonas Exotoxin A AR ORD P 14 01 03701 Abandoned
NCI E-771-2013-4-PCT-01 Modified Pseudomonas Exotoxin A PCT PCT COMB PCT/US14/058941 Expired
NIMH E-252-2014-0-US-01 Magnetic Resonance Magnification Imaging US 62/059,520 Abandoned
NCI E-771-2013-4-CA-09 Modified Pseudomonas Exotoxin A CA National Stage 2926215 Abandoned
NCI E-233-2014-0-DK-13 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation DK EP 14796317.7 Issued
NCI E-233-2014-0-BE-12 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation BE EP 14796317.7 Issued
NCI E-233-2014-0-EP-05 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP National Stage 14796317.7 Issued
NCI E-233-2014-0-IT-16 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation IT EP 14796317.7 Issued
NCI E-233-2014-0-DE-15 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation DE EP 14796317.7 Issued
NCI E-233-2014-0-FR-14 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation FR EP 14796317.7 Issued
NCI E-233-2014-0-NO-18 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation NO EP 14796317.7 Issued
NCI E-233-2014-0-SE-20 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation SE EP 14796317.7 Issued
NCI E-233-2014-0-ES-19 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation ES EP 14796317.7 Issued
NCI E-233-2014-0-NL-17 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation NL EP 14796317.7 Issued
NCI E-233-2014-0-CH-21 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation CH EP 14796317.7 Issued
NCI E-233-2014-0-GB-22 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation GB EP 14796317.7 Issued
CC E-170-2012-0-US-06 LARGE VOLUME, CONFORMAL HYPERTHERMIA WITH MAGNETIC RESONANCE-GUIDED HIGH INTENSITY FOCUSED ULTRASOUND US National Stage 14/390,181 11116405 Issued PDF
NCI E-229-2014-0-AU-02 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation AU National Stage 2014407540 Issued
NCI E-229-2014-0-US-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION US National Stage 15/515,055 10973894 Issued PDF
NCI E-233-2014-0-AU-02 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation AU National Stage 2014407539 Issued
NCI E-233-2014-0-JP-06 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation JP National Stage 2017-517662 Issued
NCI E-229-2014-0-JP-06 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation JP National Stage 2017-517677 Issued
NCI E-086-2012-2-US-05 Methods For Generation Of Pluripotent And Multipotent Cells US National Stage 14/390,134 10407665 Issued PDF
NICHD E-084-2012-0-US-04 Polarmetric Accessory For Colposcope US National Stage 14/390,354 9801536 Issued PDF
NCI E-229-2014-0-PCT-01 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation PCT PCT PCT/US2014/058805 Expired
NCI E-233-2014-0-PCT-01 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation PCT PCT PCT/US2014/058796 Expired
NCI E-229-2014-0-CN-04 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation CN National Stage 201480082922.X Pending
NCI E-233-2014-0-CN-04 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation CN National Stage 201480082932.3 Pending
NCI E-229-2014-0-EP-05 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation EP National Stage 14790878.4 Abandoned
NCI E-229-2014-0-CA-03 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation CA National Stage 2963364 Pending
NCI E-771-2013-4-VE-07 Modified Pseudomonas Exotoxin A VE ORD 1162-14 Abandoned
NHLBI E-342-2013-0-EP-04 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings EP National Stage 14790863.6 Issued
NHLBI E-342-2013-0-IE-12 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings IE EP 14790863.6 Issued
NHLBI E-342-2013-0-FR-10 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings FR EP 14790863.6 Issued
NHLBI E-342-2013-0-DE-09 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings DE EP 14790863.6 Issued
NHLBI E-342-2013-0-CH-08 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings CH EP 14790863.6 Issued
NHLBI E-342-2013-0-GB-11 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings GB EP 14790863.6 Issued
NIDCR E-619-2013-0-GB-07 00METHODS OF MODULATING ERYTHROPOIESIS WITH ARGININE VASOPRESSIN RECEPTOR 1B MOLECULES GB EP 14790866.9 Abandoned
NIDCR E-619-2013-0-EP-04 00METHODS OF MODULATING ERYTHROPOIESIS WITH ARGININE VASOPRESSIN RECEPTOR 1B MOLECULES EP National Stage 14790866.9 Abandoned
NIDCR E-619-2013-0-FR-06 00METHODS OF MODULATING ERYTHROPOIESIS WITH ARGININE VASOPRESSIN RECEPTOR 1B MOLECULES FR EP 14790866.9 Abandoned
NIDCR E-619-2013-0-DE-05 00METHODS OF MODULATING ERYTHROPOIESIS WITH ARGININE VASOPRESSIN RECEPTOR 1B MOLECULES DE EP 14790866.9 Abandoned
NIAID E-019-2007-2-KR-18 Vaccines Against Potential Pandemic Strains Of Influenza KR DIV 10-2014-7031694 Abandoned